TIE-2 receptor agonists - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “TIE-2 receptor agonists - Pipeline Insight, 2022” report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in TIE-2 receptor agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
TIE-2 receptor agonists: Overview
The tie receptors form another family of receptor tyrosine kinases. They are important for the regulation of angiogenesis together with the ligands of the tie-2 receptor, the Angiopoietins. The tie tyrosine kinase receptors, like the VEGF receptors, form the only receptor families that are predominantly expressed on endothelial cells. Most studies have focused on Ang-1 and Ang-2 which bind the Tie2 receptor and have the best characterized roles in angiogenesis. The roles of Ang-1 and Ang-2 signaling are complex and context dependent. Ang-1 binds and directly activates the Tie2 receptor, and this can have pro-angiogenic roles, stimulating EC sprouting and vessel growth as well as being correlated with vessel density in a variety of tumors.
Report Highlights
This segment of the TIE-2 receptor agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TIE-2 receptor agonists Emerging Drugs
Further product details are provided in the report……..
TIE-2 receptor agonists: Therapeutic Assessment
This segment of the report provides insights about the different TIE-2 receptor agonists drugs segregated based on following parameters that define the scope of the report, such as:
TIE-2 receptor agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TIE-2 receptor agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIE-2 receptor agonists drugs.
TIE-2 receptor agonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “TIE-2 receptor agonists - Pipeline Insight, 2022” report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in TIE-2 receptor agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
TIE-2 receptor agonists: Overview
The tie receptors form another family of receptor tyrosine kinases. They are important for the regulation of angiogenesis together with the ligands of the tie-2 receptor, the Angiopoietins. The tie tyrosine kinase receptors, like the VEGF receptors, form the only receptor families that are predominantly expressed on endothelial cells. Most studies have focused on Ang-1 and Ang-2 which bind the Tie2 receptor and have the best characterized roles in angiogenesis. The roles of Ang-1 and Ang-2 signaling are complex and context dependent. Ang-1 binds and directly activates the Tie2 receptor, and this can have pro-angiogenic roles, stimulating EC sprouting and vessel growth as well as being correlated with vessel density in a variety of tumors.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence TIE-2 receptor agonists R&D. The therapies under development are focused on novel approaches for TIE-2 receptor agonists.
This segment of the TIE-2 receptor agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TIE-2 receptor agonists Emerging Drugs
- AV-001: Vasomune Therapeutics
- Razuprotafib: Aadi Biosciences
Further product details are provided in the report……..
TIE-2 receptor agonists: Therapeutic Assessment
This segment of the report provides insights about the different TIE-2 receptor agonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on TIE-2 receptor agonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
TIE-2 receptor agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TIE-2 receptor agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIE-2 receptor agonists drugs.
TIE-2 receptor agonists Report Insights
- TIE-2 receptor agonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing TIE-2 receptor agonists drugs?
- How many TIE-2 receptor agonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TIE-2 receptor agonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TIE-2 receptor agonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TIE-2 receptor agonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Aadi Biosciences
- Vasomune Therapeutics
- AsclepiX Therapeutics
- Q BioMed
- PharmAbcine
- Mannin Research
- Razuprotafib
- AV 001
- Gersizangitide
- MAN 19
- PMC 403
- MAN 11
- ARP 1536
Introduction
Executive Summary
TIE-2 receptor agonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TIE-2 receptor agonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Razuprotafib: Aadi Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AV 001: Vasomune Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
PMC 403: PharmAbcine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TIE-2 receptor agonists Key Companies
TIE-2 receptor agonists Key Products
TIE-2 receptor agonists- Unmet Needs
TIE-2 receptor agonists- Market Drivers and Barriers
TIE-2 receptor agonists- Future Perspectives and Conclusion
TIE-2 receptor agonists Analyst Views
TIE-2 receptor agonists Key Companies
Appendix
Executive Summary
TIE-2 receptor agonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TIE-2 receptor agonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Razuprotafib: Aadi Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AV 001: Vasomune Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
PMC 403: PharmAbcine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TIE-2 receptor agonists Key Companies
TIE-2 receptor agonists Key Products
TIE-2 receptor agonists- Unmet Needs
TIE-2 receptor agonists- Market Drivers and Barriers
TIE-2 receptor agonists- Future Perspectives and Conclusion
TIE-2 receptor agonists Analyst Views
TIE-2 receptor agonists Key Companies
Appendix